At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2015 financial results, reviews the Company's recent progress, and provides an outlook for 2016 for its pulmonary disease development pipeline. "2015...
Dear Fellow Shareholders, Continuing our Momentum As Pulmatrix moves into 2016, we wanted to describe to our shareholders the significant progress the Company is making—and how...
Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of...
Capsugel and Pulmatrix, Inc. ("Pulmatrix") (NASDAQ: PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel...
Pulmatrix, Inc. (NASDAQ: PULM) reports that enrollment is underway in the Company's European pilot bioequivalence study of PUR0200, a proprietary iSPERSE™ (Inhaled Small Particles Easily...